SEC Form 4
Acrivon Therapeutics, Inc. (ACRV) insider trading
In the 12 months to Nov 20, 2026, 7 ACRV insiders reported open-market sales of $39.8K across 9 filings; 3 insiders bought $114.3K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $39.8K
- 9 filings · 7 insiders
- Open-market purchases
- $114.3K
- 3 filings
Who traded ACRV, and when
- Purchase
- Sale
ACRV daily close from Nov 20, 2025 to Nov 20, 2026, between $1.15 and $3.01, last $1.15. 9 sale and 3 purchase filings by 7 insiders, marked at their filing dates. Kristina Masson, EVP - Business Operations: sold $33.4K and bought $82.1K across 3 filings, first filed Jan 16, 2026, last Aug 27, 2026. Eric Devroe, Chief Operating Officer: sold $1.2K and bought $17.2K across 2 filings, first filed Jan 15, 2026, last Aug 20, 2026. Adam D. Levy, Chief Financial Officer: sold $1.8K and bought $15.0K across 2 filings, first filed Jan 16, 2026, last Aug 6, 2026. Mary Miller, Chief Legal Officer: sold $1.4K across 2 filings, first filed Jul 23, 2026, last Aug 20, 2026. Peter Blume-Jensen, President and CEO: sold $973 across 1 filing, first filed Aug 20, 2026, last Aug 20, 2026. Erick Gamelin, Chief Development Officer: sold $804 across 1 filing, first filed Aug 20, 2026, last Aug 20, 2026. Katharine Peterson, Chief Accounting Officer: sold $203 across 1 filing, first filed Aug 20, 2026, last Aug 20, 2026.
Largest mark · tap a row for others
Kristina Masson · EVP - Business Operations
Purchase $82,124
49,000 shares at $1.68 avg
Filed Jan 16, 2026 · traded Jan 14
Close on filing date $1.98
Kristina Masson · EVP - Business Operations
EVP - Business Operations
$33.4K sold$82.1K boughtEric Devroe · Chief Operating Officer
Chief Operating Officer
$1.2K sold$17.2K boughtAdam D. Levy · Chief Financial Officer
Chief Financial Officer
$1.8K sold$15.0K boughtMary Miller · Chief Legal Officer
Chief Legal Officer
$1.4K soldPeter Blume-Jensen · President and CEO
President and CEO
$973 soldErick Gamelin · Chief Development Officer
Chief Development Officer
$804 soldKatharine Peterson · Chief Accounting Officer
Chief Accounting Officer
$203 soldOpen-market trades
12 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Kristina Masson | EVP - Business Operations | $33.4K | $82.1K | 3 | — | |
| Eric Devroe | Chief Operating Officer | $1.2K | $17.2K | 2 | — | |
| Adam D. Levy | Chief Financial Officer | $1.8K | $15.0K | 2 | — | |
| Mary Miller | Chief Legal Officer | $1.4K | — | 2 | — | |
| Peter Blume-Jensen | President and CEO | $973 | — | 1 | — | |
| Erick Gamelin | Chief Development Officer | $804 | — | 1 | — | |
| Katharine Peterson | Chief Accounting Officer | $203 | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Kristina Masson EVP - Business Operations | Sale | 14,036 | $2.21 | $31.0K | 2,230,052 | |
traded | Kristina Masson EVP - Business Operations | Sale | 1,229 | $2.01 | $2.5K | 2,244,088 | |
traded | Peter Blume-Jensen President and CEO | Sale | 484 | $2.01 | $973 | 385,859 | |
traded | Eric Devroe Chief Operating Officer | Sale | 604 | $2.01 | $1.2K | 146,349 | |
traded | Erick Gamelin Chief Development Officer | Sale | 400 | $2.01 | $804 | 52,592 | |
traded | Mary Miller Chief Legal Officer | Sale | 185 | $2.01 | $372 | 82,009 | |
traded | Katharine Peterson Chief Accounting Officer | Sale | 101 | $2.01 | $203 | 18,033 | |
traded | Adam D. Levy Chief Financial Officer | Sale | 1,142 | $1.57 | $1.8K | 66,008 | |
traded | Mary Miller Chief Legal Officer | Sale | 573 | $1.76 | $1.0K | 82,194 | |
traded | Adam D. Levy Chief Financial Officer | Purchase | 8,832 | $1.70 | $15.0K | 20,983 | |
traded | Kristina Masson EVP - Business Operations | Purchase | 49,000 | $1.68 | $82.1K | 2,095,771 | |
traded | Eric Devroe Chief Operating Officer | Purchase | 10,000 | $1.72 | $17.2K | 75,308 |
GET /stocks/filings/vX/form-4?tickers=ACRV&filing_date.gte=2025-11-20&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ACRV"
],
"issuer_cik": "0001781174",
"owner_cik": "0001950501",
"accession_number": "0000905148-26-003968",
"form_type": "4",
"filing_date": "2026-08-27",
"period_of_report": "2026-08-25",
"issuer_name": "Acrivon Therapeutics, Inc.",
"issuer_trading_symbol": "ACRV",
"owner_name": "Masson Kristina",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP - Business Operations",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-25",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 14036,
"transaction_price_per_share": 2.2064,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 2230052,
"transaction_value": 30969.0304,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."
},
{
"id": "F2",
"description": "The price reported in Column 4 above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $2.17 to $2.25, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4."
},
{
"id": "F3",
"description": "These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."
}
]
},
{
"tickers": [
"ACRV"
],
"issuer_cik": "0001781174",
"owner_cik": "0001950499",
"accession_number": "0000905148-26-003968",
"form_type": "4",
"filing_date": "2026-08-27",
"period_of_report": "2026-08-25",
"issuer_name": "Acrivon Therapeutics, Inc.",
"issuer_trading_symbol": "ACRV",
"owner_name": "Blume-Jensen Peter",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President and CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-25",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 14036,
"transaction_price_per_share": 2.2064,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 2230052,
"transaction_value": 30969.0304,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."
},
{
"id": "F2",
"description": "The price reported in Column 4 above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $2.17 to $2.25, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4."
},
{
"id": "F3",
"description": "These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 42 records
- Tax withholding17 records
- Tax withholding (sold to cover)8 records
- Grants and awards17 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Acrivon Therapeutics, Inc.'s CEO sold stock?
Yes. Peter Blume-Jensen (CEO) sold 484 shares ($973) in Aug 2026.
How current is ACRV’s insider data?
These are ACRV Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ACRV insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ACRV every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.